Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | RAC1 | P63000 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14727986 | 0.82 | TRPM4 (0.33) | — | |
| SCHEMBL14727985 | 0.82 | — | — | |
| SCHEMBL10672662 | 0.78 | KMT2A (0.37) | — | |
| SCHEMBL9218101 | 0.76 | CYP2A6 (0.50) | CYP2A6RAC1CYP1A2GPR3ALDH1A1 | |
| SCHEMBL4130358 | 0.73 | TDP1 (0.50) | CYP2A6CYP1A2 | |
| SCHEMBL23682198 | 0.73 | KMT2A (0.46) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL20125555 | 0.73 | AGTR1 (0.41) | ALDH1A1HPGDHSD17B10 | |
| SCHEMBL21665132 | 0.72 | KDM4E (0.34) | CYP1A2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL14623161 | 0.72 | MYC (0.37) | CYP1A2HPGD | |
| SCHEMBL21338518 | 0.72 | LMNA (0.47) | CYP1A2HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | CYP2A6 4388/4885RAC1 437/4885CYP1A2 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.